Hepatocellular carcinoma. An overview
Tóm tắt
Từ khóa
Tài liệu tham khảo
el-Serag, 2001, Epidemiology of hepatocellular carcinoma, Clin Liver Dis, 5, 87, 10.1016/S1089-3261(05)70155-0
Marrero, 2003, Hepatocellular carcinoma, Curr Opin Gastroenterol, 19, 243, 10.1097/00001574-200305000-00007
El-Serag, 1999, Rising incidence of hepatocellular carcinoma in the United States, N Engl J Med, 340, 745, 10.1056/NEJM199903113401001
Horie, 2003, National survey of hepatocellular carcinoma in heavy drinkers in Japan, Alcohol Clin Exp Res, 27, 32, 10.1097/01.ALC.0000078605.33391.20
Uetake, 2003, Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen-and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection, Alcohol Clin Exp Res, 27, 47S, 10.1097/01.ALC.0000079449.47468.B0
Goncalves, 1997, Hepatocellular carcinoma in Brazil: report of a national survey (Florianopolis, SC, 1995), Rev Inst Med Trop Sao Paulo, 39, 165, 10.1590/S0036-46651997000300008
Cortes-Espinosa, 1997, Hepatocellular carcinoma and hepatic cirrhosis in Mexico: a 25 year necroscopy review, Hepatogastroenterology, 44, 1401
Velazquez, 2003, Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis, Hepatology, 37, 520, 10.1053/jhep.2003.50093
Bailey, 2002, Hepatocellular carcinoma: predisposing conditions and precursor lesions, Gastroenterol Clin North Am, 31, 641, 10.1016/S0889-8553(02)00017-1
Mendez-Sanchez, 2004, Etiology of liver cirrhosis in Mexico, Ann Hepatol, 3, 30, 10.1016/S1665-2681(19)32122-2
Mendez-Sanchez, 2005, Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data, Ann Hepatol, 4, 52, 10.1016/S1665-2681(19)32086-1
Libbrecht, 2005, Preneoplastic lesions in human hepatocarcinogenesis, Liver Int, 25, 16, 10.1111/j.1478-3231.2005.01016.x
Hytiroglou, 2004, Morphological changes of early human hepato-carcinogenesis, Semin Liver Dis, 24, 65, 10.1055/s-2004-823097
Borzio, 2003, Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development, J Hepatol, 39, 208, 10.1016/S0168-8278(03)00190-9
Kaplan, 2003, Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes, Clin Liver Dis, 7, 683, 10.1016/S1089-3261(03)00060-6
Zein, 1996, Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b, Am J Gastroenterol, 91, 2560
Tarao, 2002, Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis, Cancer, 94, 1787, 10.1002/cncr.10391
Bosch, 2005, Epidemiology of hepatocellular carcinoma, Clin Liver Dis, 9, 191, 10.1016/j.cld.2004.12.009
Bressac, 1991, Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa, Nature, 350, 429, 10.1038/350429a0
Lee, 2000, Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma, Oncogene, 19, 3717, 10.1038/sj.onc.1203694
Fracanzani, 2001, Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease, Hepatology, 33, 647, 10.1053/jhep.2001.22506
Potempa, 1994, The serpin superfamily of pro-teinase inhibitors: structure, function, and regulation, J Biol Chem, 269, 15957, 10.1016/S0021-9258(17)33954-6
Parmar, 2000, Alpha-1-antitrypsin deficiency, the serpinopathies and conformational disease, J R Coll Physicians Lond, 34, 295
Ludwig, 1980, Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease, Mayo Clin Proc, 55, 434
Bellentani, 2000, Prevalence of and risk factors for hepatic steatosis in Northern Italy, Ann Intern Med, 132, 112, 10.7326/0003-4819-132-2-200001180-00004
Marceau, 1999, Liver pathology and the metabolic syndrome X in severe obesity., J Clin Endocrinol Metab, 84, 1513, 10.1210/jcem.84.5.5661
Caldwell, 1999, Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease, Hepatology, 29, 664, 10.1002/hep.510290347
Mendez-Sanchez, 2004, The relationship of overweight and obesity to high mortality rates from liver cirrhosis in Mexico, Ann Hepatol, 3, 66, 10.1016/S1665-2681(19)32111-8
Calle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, N Engl J Med, 348, 1625, 10.1056/NEJMoa021423
Bugianesi, 2002, Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma, Gastroenterology, 123, 134, 10.1053/gast.2002.34168
Ratziu, 2002, Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis, Hepatology, 35, 1485, 10.1053/jhep.2002.33324
Nair, 2002, Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis, Hepatology, 36, 150, 10.1053/jhep.2002.33713
Ozturk, 1999, Genetic aspects of hepatocellular carcinogenesis, Semin Liver Dis, 19, 235, 10.1055/s-2007-1007113
Macdonald, 2001, Pathogenesis of hepatocellular carcinoma, Clin Liver Dis, 5, 69, 10.1016/S1089-3261(05)70154-9
Sohara, 2000, Esophageal metastasis of hepatocellular carcinoma, Gastrointest Endosc, 51, 739, 10.1067/mge.2000.105728
Befeler, 2002, Hepatocellular carcinoma: diagnosis and treatment, Gastroenterology, 122, 1609, 10.1053/gast.2002.33411
Ryder, 2003, Guidelines for the diagnosis and treatment of hepato-cellular carcinoma (HCC) in adults, Gut, 52, iii1
Johnson, 2001, The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma, Clin Liver Dis, 5, 145, 10.1016/S1089-3261(05)70158-6
Weissenberger, 2000, Is there any correlation between MDR1, GST-pi-expression and CEA, Anticancer Res, 20, 5139
Taheri, 2000, Self recognition in the Ig superfamily. Identification of precise subdomains in carcinoembryonic antigen required for intercellular adhesion, J Biol Chem, 275, 26935, 10.1016/S0021-9258(19)61463-8
Levy, 2002, Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto, Gut, 50, 881, 10.1136/gut.50.6.881
Ueno, 2001, Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program, Hepatology, 34, 529, 10.1053/jhep.2001.27219
Grieco, 2005, Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre, Gut, 54, 411, 10.1136/gut.2004.048124
Aguayo, 2001, Nonsurgical treatment of hepatocellular carcinoma, Clin Liver Dis, 5, 175, 10.1016/S1089-3261(05)70160-4
Geschwind, 2003, Chemoembolization of hepatocellular carcinoma: results of a metaanalysis, Am J Clin Oncol, 26, 344, 10.1097/01.COC.0000020588.20717.BB
Yoshida, 1999, Interferon therapy reduces the risk for hepatocel-lular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy, Ann Intern Med, 131, 174, 10.7326/0003-4819-131-3-199908030-00003
Rust, 2001, Locoregional management of hepatocellular carcinoma. Surgical and ablation therapies, Clin Liver Dis, 5, 161, 10.1016/S1089-3261(05)70159-8
Mazzaferro, 1996, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N Engl J Med, 334, 693, 10.1056/NEJM199603143341104
Bruix, 2002, Prognostic prediction and treatment strategy in hepatocellular carcinoma, Hepatology, 35, 519, 10.1053/jhep.2002.32089
Llovet, 1999, Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation, Hepatology, 30, 1434, 10.1002/hep.510300629
Bruix, 1996, Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure, Gastroenterology, 111, 1018, 10.1016/S0016-5085(96)70070-7
Okada, 1994, Predictive factors for postoperative recurrence of hepatocellular carcinoma, Gastroenterology, 106, 1618, 10.1016/0016-5085(94)90419-7
Yamasaki, 1996, A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma, Jpn J Cancer Res, 87, 206, 10.1111/j.1349-7006.1996.tb03160.x
Farges, 2003, Portal vein embolization before right hepatectomy: prospective clinical trial, Ann Surg, 237, 208, 10.1097/01.SLA.0000048447.16651.7B